ALKERMES, INC.
A Phase 1 Safety Study in Adults With Schizophrenia
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02804568
- Locations
- 🇺🇸
Alkermes Investigational Site, Dayton, Ohio, United States
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02696434
- Locations
- 🇺🇸
John Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Neuroscience Research Institute, Inc., Winfield, Illinois, United States
🇺🇸Segal Institute for Clinical Research, Lauderhill, Florida, United States
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 561
- Registration Number
- NCT02694328
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 281
- Registration Number
- NCT02669758
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02636842
- Locations
- 🇺🇸
Alkermes Investigative Site, Dallas, Texas, United States
🇺🇸Alkermes Investigational Site, Marlton, New Jersey, United States
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02634346
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02634320
- Locations
- 🇺🇸
Alkermes Investigational Site, DeSoto, Texas, United States
A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02545439
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
- Conditions
- Opioid Use Disorder
- Interventions
- Drug: NTX/BUPDrug: PBO-N/PBO-BDrug: NTX/PBO-B
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT02537574
- Locations
- 🇺🇸
TRY Research, Maitland, Florida, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
🇺🇸University Of Pennsylvania - Treatment Research Center, Philadelphia, Pennsylvania, United States
A Water Consumption Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02521857
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States